ArticleBMC bioinformatics2021
Learning curves for drug response prediction in cancer cell lines.
Article in BMC bioinformatics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Integrative Transcriptomic and Machine Learning Analysis of ecDNA-Associated Features for Studying Chemotherapy Resistance in TNBC.bioRxiv : the preprint server for biology · 2026Article
- Monotherapy cancer drug-blind response prediction is limited to intraclass generalization.PLoS computational biology · 2026Article
- Benchmarking community drug response prediction models: datasets, models, tools, and metrics for cross-dataset generalization analysis.Briefings in bioinformatics · 2026Article
- Exploring Artificial Intelligence's Potential to Enhance Conventional Anticancer Drug Development.Drug development research · 2025Review
- Understanding the sources of performance in deep drug response models reveals insights and improvements.Bioinformatics (Oxford, England) · 2025Article
- A precision oncology-focused deep learning framework for personalized selection of cancer therapy.bioRxiv : the preprint server for biology · 2024Article
- Improving drug response prediction via integrating gene relationships with deep learning.Briefings in bioinformatics · 2024Article
- teemi: An open-source literate programming approach for iterative design-build-test-learn cycles in bioengineering.PLoS computational biology · 2024Article
- Comparison of multiple modalities for drug response prediction with learning curves using neural networks and XGBoost.Bioinformatics advances · 2024Article
- Improving model transferability for clinical note section classification models using continued pretraining.Journal of the American Medical Informatics Association : JAMIA · 2023Article
- AI-accelerated protein-ligand docking for SARS-CoV-2 is 100-fold faster with no significant change in detection.Scientific reports · 2023Article
- Deep learning methods for drug response prediction in cancer: Predominant and emerging trends.Frontiers in medicine · 2023Review
- Data augmentation and multimodal learning for predicting drug response in patient-derived xenografts from gene expressions and histology images.Frontiers in medicine · 2023Article
- A cross-study analysis of drug response prediction in cancer cell lines.Briefings in bioinformatics · 2022Article
- Converting tabular data into images for deep learning with convolutional neural networks.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundMotivated by the size and availability of cell line drug sensitivity data, researchers have been developing machine learning (ML) models for predicting drug response to advance cancer treatment. As drug sensitivity studies continue generating drug response data, a common question is whether the generalization performance of existing prediction models can be further improved with more training data.
methodsWe utilize empirical learning curves for evaluating and comparing the data scaling properties of two neural networks (NNs) and two gradient boosting decision tree (GBDT) models trained on four cell line drug screening datasets. The learning curves are accurately fitted to a power law model, providing a framework for assessing the data scaling behavior of these models.
resultsThe curves demonstrate that no single model dominates in terms of prediction performance across all datasets and training sizes, thus suggesting that the actual shape of these curves depends on the unique pair of an ML model and a dataset. The multi-input NN (mNN), in which gene expressions of cancer cells and molecular drug descriptors are input into separate subnetworks, outperforms a single-input NN (sNN), where the cell and drug features are concatenated for the input layer. In contrast, a GBDT with hyperparameter tuning exhibits superior performance as compared with both NNs at the lower range of training set sizes for two of the tested datasets, whereas the mNN consistently performs better at the higher range of training sizes. Moreover, the trajectory of the curves suggests that increasing the sample size is expected to further improve prediction scores of both NNs. These observations demonstrate the benefit of using learning curves to evaluate prediction models, providing a broader perspective on the overall data scaling characteristics.
conclusionsA fitted power law learning curve provides a forward-looking metric for analyzing prediction performance and can serve as a co-design tool to guide experimental biologists and computational scientists in the design of future experiments in prospective research studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.